1 / 46

Risk of second malignancy and cardio-vascular disease after Hodgkin’s lymphoma and breast cancer

Risk of second malignancy and cardio-vascular disease after Hodgkin’s lymphoma and breast cancer. Flora E. van Leeuwen Department of Epidemiology Netherlands Cancer Institute, Amsterdam. Survival Hodgkin’s lymphoma (Kaplan 1978). megavoltage +/- chemotherapy. orthovoltage. no therapy.

ave
Download Presentation

Risk of second malignancy and cardio-vascular disease after Hodgkin’s lymphoma and breast cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Risk of second malignancy and cardio-vascular disease after Hodgkin’s lymphoma and breast cancer Flora E. van Leeuwen Department of Epidemiology Netherlands Cancer Institute, Amsterdam

  2. Survival Hodgkin’s lymphoma(Kaplan 1978) megavoltage +/- chemotherapy orthovoltage no therapy years

  3. 8-year Event Free Survival 8-year Overall Survival trialno H1 1964 H2 1972 H5 1977 H6 1982 H7 1988 H8 1993 year Survival in 6 consecutive EORTC-trials on Hodgkin’s lymphoma early stage

  4. Literature 1970-1995 Risk of second cancers following HD • Strongly increased risk of ANLL following MOPP-chemotherapy or related regimens • Excess risk of ANLL concentrated in 2-10 year period following treatment • Strongly increased risk of NHL; related to therapy? • In 10-year survivors who received radiotherapy: moderately increased risk of various solid tumors (lung, breast, stomach, colon, thyroid, melanoma)

  5. Dores 2002 (n=32,591) Site or Type Obs O/E Excess cases / 10.000 pat. / yr. 2153 249 162 1726 80 129 377 234 37 47 9 32 52 2.3 9.9 5.5 2.0 1.9 1.6 2.9 2.0 2.0 4.1 3.8 5.1 1.7 47.2 8.8 5.2 33.1 1.5 2.0 9.7 10.5 1.6 1.4 0.3 1.0 0.9 All cancers Leukemia NHL Solid tumors Stomach Colon Lung Female breast Uterine cervix Thyroid Bone Soft tissue Melanoma Relative Risk of Second Cancers after HL Adapted from Dores JCO 2002; 20:3484

  6. Dutch HD cohortRR of SCs in 1,253 1-yr survivors of HD, age <40 yrs, according to follow-up interval (n=1253) Van Leeuwen JCO 2000; 18: 487

  7. Relative risks of solid tumors by age at HL diagnosis • International cohort study: 32,591 HL patients • 1,111 25-years survivors, population-based Adapted from Dores JCO 2002; 20:3484

  8. Risk of breast cancer after Hodgkin’s Lymphoma (HL): a 30-year follow-up study F.E. van Leeuwen1, W.J. Klokman1, M.B. van ‘t Veer3, B.M.P. Aleman2 Departments of Epidemiology1 and Radiotherapy2, Netherlands Cancer Institute, Amsterdam; Department of Haematology3, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

  9. What’s the problem? Mantle field 1974, BC= Site of subsequent breast cancer 2002 Mantle field RT

  10. Dutch study of SC risk after HL • Study population • 1,939 HL patients admitted to NKI (Amsterdam) or DDHK (Rotterdam) between 1966 and 1986 (J Clin Oncol 1994;12:312) • 1,253 patients under age 41 at HL diagnosis, 1-year survivors(J Clin Oncol 2000;18:487) • Updated follow-up 2003-2005 • Cohort expanded with 437 patients treated 1987-1995

  11. Characteristics of study population • Treatment groups • RT only 27% • CT only 4% • Initial RT+CT 35% • Salvage RT+CT 33% • 82% received RT including mediastinum • 30% received anthracyclines

  12. Dutch HL cohortRR of breast cancer in 634 female survivors of HL, by age at diagnosis Absolute excess risk bij RT  20 = 77 / 10.000 patiënten/jaar Betekent: 7.7 extra gevallen van borstkanker per 100 patiënten gevolgd voor 10 jaar (0.4 patiënt verwacht)

  13. RR and AER of breast cancer per 10,000 patients/year by follow-up interval 14 280 260 12 AER RR 240 220 10 200 180 8 160 140 6 120 100 4 80 60 2 40 20 0 0 1-4yrs 5-9yrs 10-14yrs 15-19yrs 20-24yrs 25-29yrs >=30yrs 1-4yrs 5-9yrs 10-14yrs 15-19yrs 20-24yrs 25-29yrs >=30yrs AER= absolute excess risk, increases with follow-up because the background risk increases RR = observed / expected (gen. population)

  14. Cumulative risk of breast cancer by age at first treatment

  15. Dutch HL cohortRR of breast cancer in 634 female survivors of HL, 40 yrs at diagnosis, by treatment

  16. van Leeuwen JNCI 2003: 95;971

  17. Conclusion breast cancer after HL • Excess risk of breast cancer remains strongly increased for at least 35 years. • Although the RR levels off at older ages, the absolute excess risk remains high at older ages. • Risk increases with higher radiation dose • CT-induced premature menopause strongly decreases breast cancer risk.

  18. Recommendations • Screening for breast cancer 5-8 years after RT for HL before age 40 - Attained age 25 • Yearly mammography • Clinical breast examination • Echo, MRI? • Breast self examination

  19. Lung cancer after HD Joint effects of smoking and treatmentTravis et al. JNCI 2002; 94:182 • Risks from smoking multiply risks from treatment • Smoking is the major cause of lung cancer (only 7 out of 222 cases were never smokers)

  20. Cardiovascular morbidity in long-term survivors of Hodgkin’s Lymphoma Berthe M.P. Aleman, Sandra van den Belt-Dusebout, Marieke de Bruin, Flora van Leeuwen. Netherlands Cancer Institute, Amsterdam

  21. Treatment-related cardiovascular damage • Chemotherapy (anthracyclines) • Radiotherapy

  22. Mechanisms heart diseases Radiotherapy • Coronary artery disease: endothelial cell death (apoptosis) • Pericardial fibrosis (increased capillary permeability, inhibition of local fibrinolytic mechanism) Anthracyclines • Direct damage to the myoepithelium

  23. Radiation-associated heart diseases • Coronary artery disease • Myocardial dysfunction • Valvular heart disease • Pericardial disease • Electrical conduction abnormalities

  24. Study population 2689 patients treated for HL in NKI-AVL or Erasmus MC between 1965 and 1995 2053 5-year survivors 1013 patients <31 years at diagnosis HL

  25. Characteristics of study population • Treatment groups • RT only 27% • CT only 4% • Initial RT+CT 35% • Salvage RT+CT 33% • 82% received RT including mediastinum • 30% received anthracyclines

  26. CVD incidence in HL survivors (n=1013)Results for specific cardiovascular diseases * Absolute Excess Risk per 10.000 patients/year ¶ 36 patients developed both AP and MI † RR = observed / expected ratio

  27. Incidence of myocardial infarction in HL survivors Results by treatment (n=1013)

  28. Incidence of myocardial infarction in HL survivors Results by treatment (n=1013)

  29. Heart failure incidence in HL survivors Results by treatment (n=1013)

  30. Incidence MI in HL survivors (n=1013)Results by follow-up interval RR AER AER per 10.000 patients/ year AER > 25 jaar fup = 92 / 10.000 pat. / jr  23 extra gevallen (7 gevallen verwacht) per 100 pat. gevolgd voor 25 jr. Abs. incidentie is 30 / 100 pat. / 25 jr

  31. CVD incidence in HL survivors (n=1013)Results by age at diagnosis

  32. Conclusions • 5-fold increase of coronary artery disease risk in 5-year Hodgkin survivors treated  age 31 • Stronger increase of AP and HF in patients treated at younger ages • Constant RRs with longer follow-up  AERs  • No increased risk after anthracycline containing chemotherapy

  33. Implications for clinical practice • Alertness regarding complaints, in particular for patients treated at young age • Intervention in classical CVD risk factors • Screening? • Chemoprevention??

  34. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer Maartje J. Hooning, Akke Botma, Berthe M.P. Aleman, Jan G.M. Klijn*, Flora E. van Leeuwen *

  35. Introduction • More use of adjuvant RT, CT and HT; early detection • More patients with long survival • Late side effects: • Cardiovascular disease • Second malignancies

  36. Treatment of operable breast cancer • 1970s: Mastectomy ’80<: BCT (surgery + breast RT) • RT on locoregional fields (on indication) • End 1970s: adjuvant systemic treatment (CT, HT)

  37. Recent literature: CVD after RT for BC Older studies: risk  after postmastectomy RT * Endpoint: also incidence of CVD

  38. Need for studies : • Long-term follow-up • Information on specific RT fields • Information on cardiac risk factors • Incidence of CVD: - Earlier results - More events

  39. Patients and methods • 7425 patients treated for BC stage I – III • In NKI-AvL or Erasmus MC from 1970 to 1986 • All 10-year survivors: n = 4414 • Data collection: active follow-up • Initial and follow-up treatment: RT fields, CT, HT • Dates, diagnoses of CVD: MI, AP, CHF • Cardiac risk factors: smoking, hypertension, DM, hypercholesterolemia  4368 patients eligible for analysis

  40. Characteristics of patients • Median age at BC diagnosis: 49 years • Median follow-up: 17.7 years • Complete follow-up until Jan 2000: 96% • Treatment period: < 1980: 43% (n= 1882) ≥ 1980: 57% (n= 2486)

  41. Cardiovascular Disease in the Late Effects BC studygeneral population comparison *Absolute Excess Risk per 10,000 patients/year

  42. Cumulative Risk of CVD by RT and period (<1980, >= 1980) % No RT (ref) RT < 1980 (HR 1.3) RT >= 1980 (HR1.3) 10 20 30 Adjusted for age Time (years)

  43. Risk of MI* by RT field, laterality and treatment period *Cox model, adjusted for age

  44. Risk of CHF* by RT field, laterality and treatment period * Cox model, adjusted for age, CT and HT

  45. Conclusions • Also after 1979, risk of CVD  : - RT to left chest wall (MI) - RT to left- and right-sided IMC field (CHF) • For IMC field RT: left vs right-sided comparison of risks:  underestimation • RT to breast only: no increased risk • Smoking and RT: more than additive effect on risk of MI

  46. Implications • Large BC survivor population at  risk of CVD • Continued follow-up needed of BC patients treated with contemporary RT methods • Larger studies needed (population-based?) to evaluate CVD risk after breast only RT • Intervention of cardiac risk factors - esp. after RT: smoking!

More Related